List of Excipients in Branded Drug TYSABRI

« Back to Dashboard

Last updated: October 2, 2026

Tysabri’s excipient strategy is deliberately conventional: a low-complexity phosphate-buffered formulation with sodium chloride and polysorbate 80 supports a high-value monoclonal antibody without introducing novel excipient risk. The strongest commercial opportunities are not new excipients alone. They are in biosimilar-compatible formulation development, polysorbate and silicone-oil control, subcutaneous delivery, prefilled-device compatibility, aggregation reduction, and cold-chain resilience.

Tysabri Excipient Strategy, Formulation Patents, and Commercial Opportunities

What is Tysabri and which formulation is commercially protected?

Tysabri is natalizumab, a humanized monoclonal antibody targeting the alpha-4 integrin subunit. Biogen and its commercial partners market it for relapsing forms of multiple sclerosis and moderately to severely active Crohn’s disease in patients with inadequate response or intolerance to conventional therapies.

The product has two relevant administration formats:

Product format	Administration	Commercial formulation	Strategic relevance
Tysabri concentrate	300 mg in 15 mL	Diluted for intravenous infusion	Original formulation and established hospital-use product
Tysabri injection	300 mg in a prefilled syringe	Subcutaneous administration	Reduces infusion-center dependence and creates device and formulation barriers

The FDA-approved label identifies sodium chloride, phosphate-buffering salts, polysorbate 80, and water for injection as the principal inactive ingredients in the product formulation.[1] Tysabri does not rely on a novel proprietary excipient. Its defensibility comes from the combination of antibody quality, manufacturing controls, delivery format, clinical data, risk-management requirements, and regulatory complexity.

Which excipients are used in Tysabri?

Sodium chloride

Sodium chloride controls ionic strength and helps maintain an environment compatible with natalizumab stability and administration. The excipient is inexpensive, globally available, and unlikely to support meaningful standalone patent protection.

Its commercial importance is operational rather than proprietary. Suppliers compete on pharmaceutical grade, documentation, supply continuity, and low bioburden rather than molecular differentiation.

Sodium phosphate monobasic and dibasic

The phosphate salts create the formulation buffer. Buffer selection affects pH stability, protein charge distribution, aggregation behavior, and compatibility with the infusion or injection route.

For a monoclonal antibody, phosphate concentration and pH can influence:

• Aggregate formation during storage
• Adsorption to container surfaces
• Subvisible particle generation
• Viscosity and syringeability
• Compatibility with dilution media
• Stability after withdrawal from refrigerated storage

A biosimilar developer may use the same phosphate system, but it still must demonstrate product-specific comparability. The use of the same excipient does not establish biosimilarity.

Polysorbate 80

Polysorbate 80 is the most strategically significant Tysabri excipient. It reduces protein adsorption at air-liquid and container-liquid interfaces and helps limit agitation-induced aggregation.

Polysorbate 80 also creates several development risks:

• Oxidative degradation
• Hydrolysis and fatty-acid release
• Formation of subvisible particles
• Interaction with stainless steel, elastomers, or silicone oil
• Lot-to-lot variability in degradation profile
• Potential impact from peroxide impurities

For Tysabri biosimilars, polysorbate control is likely to be a larger technical issue than sodium chloride or phosphate optimization. Developers need to characterize polysorbate concentration over shelf life, degradation products, particle burden, and interaction with the delivery system.

Water for injection

Water for injection is the solvent and is not a meaningful source of formulation exclusivity. Its role is critical to sterility, endotoxin control, conductivity, and manufacturing consistency.

How strong is Tysabri’s excipient strategy?

Tysabri’s excipient strategy is strong for manufacturing simplicity but limited as a standalone exclusivity platform.

Factor	Assessment	Commercial implication
Excipient novelty	Low	Limited opportunity for composition-of-matter exclusivity
Formulation complexity	Moderate	Manageable for experienced biologics developers
Protein sensitivity	High	Natalizumab quality attributes must be tightly controlled
Polysorbate dependence	Material	Creates analytical and container-closure opportunities
IV formulation barrier	Moderate	Established biologics manufacturers can replicate the approach
Subcutaneous formulation barrier	Higher	Device, viscosity, injection force, and usability matter
Manufacturing barrier	High	Cell culture, purification, viral clearance, and comparability are demanding
Regulatory barrier	High	Biosimilar approval requires extensive analytical and clinical evidence
Excipient patent barrier	Limited to moderate	Risk depends on specific formulation and device claims

The formulation is therefore commercially replicable in principle, but the overall product is not easy to copy. A competing sponsor must reproduce a complex biologic with comparable potency, purity, aggregation profile, immunogenicity profile, and route-specific performance.

What formulation opportunities exist for Tysabri biosimilars?

The main opportunity is not to invent a radically different formulation. It is to develop a formulation that preserves natalizumab quality while improving logistics, administration, or device performance.

Polysorbate substitution or optimization

A biosimilar sponsor could evaluate polysorbate 20, poloxamers, or other surfactant systems. The regulatory burden would increase if the change affected stability, immunogenicity, extractables, or product-related impurities.

The more practical strategy is often optimization of polysorbate 80 rather than replacement. Opportunities include:

• Lower peroxide-content raw material
• Tighter fatty-acid composition specifications
• Improved supplier qualification
• Stabilized polysorbate systems
• Better assays for degradation products
• Reduced particle formation during shipping

Any replacement must be supported by comparability data and clinical risk assessment. A different surfactant may alter protein conformation or impurity profiles even if the final product meets release specifications.

Buffer optimization

Developers can test histidine, citrate, acetate, or other buffers. The objective may be improved stability, lower viscosity, better subcutaneous tolerability, or reduced interaction with the primary container.

Buffer changes may create a differentiated formulation, but they also expand the comparability package. The sponsor must show that the new system does not change natalizumab’s higher-order structure, binding activity, aggregation, charge variants, or immunogenicity risk.

Concentration and subcutaneous performance

The IV product contains 300 mg in 15 mL. A subcutaneous product requires a substantially more concentrated presentation in a smaller injection volume. This creates formulation challenges that do not arise to the same extent for IV administration:

• Higher viscosity
• Greater injection force
• Longer injection time
• Greater sensitivity to syringe and needle geometry
• Increased risk of local injection-site reactions
• More demanding container-closure compatibility

A biosimilar sponsor that matches the IV product may still need a separate development program for a subcutaneous presentation.

Lyophilization

A lyophilized natalizumab presentation could improve room-temperature handling or shipping flexibility, but it would add reconstitution steps and a new set of risks. The commercial value depends on whether cold-chain savings offset manufacturing, packaging, and administration costs.

For a product already distributed through controlled biologics channels, lyophilization is more likely to be a niche opportunity than the primary competitive strategy.

What excipient-related patents could affect Tysabri competition?

Tysabri’s core excipients are established pharmaceutical ingredients. Broad claims covering sodium chloride, phosphate buffer, polysorbate 80, or water would generally face substantial validity and prior-art challenges.

The more relevant patent risks are narrower claims directed to:

• Specific pH and buffer concentration ranges
• Defined polysorbate concentrations
• Low-peroxide polysorbate compositions
• Stabilized antibody formulations
• Reduced aggregation or particle formation
• Container-closure combinations
• Prefilled syringe systems
• Subcutaneous administration methods
• Dosing schedules and patient-selection methods
• Manufacturing processes that preserve a specified quality profile

A competitor must assess claims at the product and process level. A formulation that uses the same excipients may avoid an innovator patent if it falls outside the claimed concentration, pH, ratio, or process conditions. Conversely, a nominally different formulation may still infringe a broad functional or concentration-range claim.

Patent diligence should cover U.S., European, Japanese, Canadian, Australian, and major emerging-market families. Patent term adjustments, supplementary protection certificates, pediatric extensions, terminal disclaimers, and national-phase prosecution can change the effective barrier by jurisdiction.

When does Tysabri lose exclusivity?

Tysabri’s U.S. regulatory exclusivity is distinct from patent protection.

The FDA approved Tysabri in 2004. As a biologic, it receives 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act. That exclusivity period has expired, allowing biosimilar applications to be submitted.[2]

The product is not protected in the same way as a small-molecule drug listed in the FDA Orange Book. Biologics are generally tracked through the Purple Book, not the Orange Book. The Orange Book does not provide the principal regulatory listing mechanism for natalizumab.[3]

Exclusivity category	Tysabri position
FDA approval	2004
Reference-product biologic exclusivity	Expired
Small-molecule generic pathway	Not applicable
Biosimilar pathway	Available
Orange Book listing	Not the primary biologic listing system
Purple Book relevance	High
Patent protection	Must be assessed family by family and jurisdiction by jurisdiction
Regulatory risk after exclusivity	Biosimilar and interchangeability competition

Patent expiry dates cannot be reduced to one date without identifying the relevant patent family, jurisdiction, claim scope, patent-term adjustment, and any litigation settlement.

Are there Paragraph IV challenges to Tysabri?

Paragraph IV certifications apply to abbreviated new drug applications for small-molecule drugs under the Hatch-Waxman Act. Tysabri is a biologic, so a conventional Paragraph IV generic challenge is not the relevant route.

The competitive pathway is a biosimilar application under section 351(k) of the Public Health Service Act. Patent disputes may arise through the BPCIA patent-exchange process, often called the patent dance, or through subsequent patent litigation.

The practical distinction is important:

Issue	Small-molecule generic	Tysabri biosimilar
Primary FDA pathway	ANDA	351(k) BLA
Patent certification	Paragraph IV	BPCIA patent disclosures and litigation
Reference database	Orange Book	Purple Book
Clinical standard	Bioequivalence	Analytical, functional, pharmacokinetic, immunogenicity, and possibly clinical evidence
Interchangeability	Substitution rules vary	Requires separate interchangeability designation
Manufacturing burden	Lower than biologics	High

A company marketing a natalizumab biosimilar must evaluate both patent litigation and regulatory designation. Interchangeability may provide a commercial advantage, but it requires additional evidence and does not eliminate physician, payer, and distribution barriers.

What manufacturing and IP barriers affect natalizumab competition?

The main manufacturing barriers are upstream and product-quality related rather than excipient related.

Cell culture and purification

Natalizumab manufacturing requires a mammalian-cell expression system, controlled culture conditions, purification, viral clearance, and validated analytical methods. Small changes can affect:

• Glycosylation
• Charge heterogeneity
• Aggregation
• Fragmentation
• Host-cell proteins
• Residual DNA
• Potency
• Binding to alpha-4 integrin

A biosimilar sponsor must establish a highly similar product using orthogonal analytical methods. The excipient system cannot compensate for a materially different antibody quality profile.

Container and delivery system

The prefilled syringe creates additional IP and engineering exposure. Relevant elements include:

• Syringe barrel material
• Stopper formulation
• Silicone-oil level
• Needle shield
• Needle gauge
• Injection-force profile
• Plunger performance
• Extractables and leachables
• Shipping vibration and temperature excursions

These issues create commercial opportunities for specialty packaging companies, device manufacturers, silicone-control providers, and analytical laboratories.

Cold-chain resilience

A formulation or packaging improvement that extends allowable temperature excursions could produce measurable value. However, the sponsor must prove that excursion handling does not increase aggregation, particles, potency loss, or immunogenicity risk.

Potential offerings include:

• Stability-indicating analytical packages
• Temperature-monitoring systems
• Secondary packaging
• Insulated shipping systems
• Excursion-management protocols
• Low-particulate delivery components

What licensing deals and commercial partnerships are most relevant?

The most likely licensing opportunities involve capabilities rather than ownership of the basic excipient composition.

Potential deal categories include:

1. Natalizumab biosimilar rights for regional markets.
2. Subcutaneous delivery partnerships involving prefilled syringes or autoinjectors.
3. Polysorbate-stabilization technologies.
4. Low-particle container-closure systems.
5. Contract development and manufacturing for high-concentration monoclonal antibodies.
6. Analytical comparability platforms.
7. Cold-chain and excursion-control systems.
8. Interchangeability development programs.

A supplier with only sodium chloride or phosphate capacity has limited leverage. A supplier with validated low-peroxide polysorbate, container-closure data, device integration, and regulatory support has a stronger position.

Which companies are positioned to challenge Tysabri?

Competition is more likely to come from established biosimilar developers and global biologics manufacturers than from conventional generic-drug companies.

Relevant competitor profiles include:

• Companies with monoclonal-antibody cell-culture capacity
• Sponsors with European and U.S. biosimilar regulatory experience
• Contract manufacturers with high-concentration subcutaneous formulation capability
• Device companies with prefilled-syringe and autoinjector platforms
• Specialty pharmaceutical companies with neurology distribution networks

The commercial advantage will depend on more than manufacturing cost. Natalizumab is used in a specialized disease area with significant attention to patient risk, treatment continuity, monitoring, and physician confidence.

What revenue exposure does Tysabri face from biosimilar entry?

Tysabri revenue is exposed to erosion through several channels:

• Price discounts from biosimilar entrants
• Formularies preferring lower-cost products
• Hospital and infusion-center procurement
• Switching among stable patients
• Use of subcutaneous products to reduce administration costs
• Regional tendering
• Rebate competition
• Loss of preferred distribution status

The impact may be slower than for a conventional injectable generic because natalizumab requires specialized prescribing, monitoring, and biologic manufacturing. Subcutaneous delivery may accelerate competition if a biosimilar offers a convenient device, lower administration burden, and interchangeability designation.

The original product may retain value through:

• Physician familiarity
• Established safety-management infrastructure
• Patient support services
• Stable supply
• Clinical experience
• Contracting with payers and providers
• Retention of patients who are reluctant to switch biologics

How does Tysabri compare with competing biologic formulation strategies?

Product class	Excipient strategy	Primary competitive barrier
Tysabri natalizumab	Phosphate-buffered, polysorbate-containing aqueous formulation	Antibody manufacturing, safety infrastructure, SC device
Anti-TNF monoclonal antibodies	Often buffered aqueous formulations, sometimes high concentration	Biosimilar scale, payer substitution, device integration
Anti-CD20 antibodies	Formulation and infusion delivery vary	Manufacturing, immunogenicity, oncology and autoimmune indications
Long-acting biologics	May use depot, conjugation, or controlled-release approaches	Delivery technology and patent scope
Peptide injectables	More varied excipient and preservative systems	Device, formulation, and small-molecule competition

Tysabri’s excipient system is less differentiated than a depot or controlled-release formulation. Its advantage is a mature biologic product supported by a difficult manufacturing process and a specialized clinical-use environment.

Key Takeaways

• Tysabri uses a conventional excipient system based on sodium chloride, phosphate salts, polysorbate 80, and water for injection.
• Polysorbate 80 is the most commercially significant excipient because of degradation, particle, and container-compatibility risks.
• The strongest formulation opportunities involve subcutaneous delivery, high-concentration stability, prefilled syringes, and cold-chain resilience.
• Tysabri’s biologic exclusivity has expired, but the product remains exposed to patent, manufacturing, regulatory, and commercial barriers.
• Paragraph IV is not the applicable challenge mechanism. Biosimilar developers use the 351(k) pathway and may face BPCIA patent litigation.
• The Orange Book is not the principal source for Tysabri exclusivity analysis. The Purple Book and patent-family review are more relevant.
• Broad excipient patents are unlikely to provide strong protection. Narrow formulation, device, process, and method-of-use claims are more important.
• The best supplier opportunities are in polysorbate control, analytical comparability, container closure, subcutaneous delivery, and biologics manufacturing.

FAQs

Can a biosimilar use the same excipients as Tysabri?

Yes. A biosimilar may use the same excipients, but it must establish analytical and functional similarity and demonstrate that the formulation does not create clinically meaningful differences.

Is polysorbate 80 essential to natalizumab stability?

It is an important stabilizing surfactant in the approved formulation, but a biosimilar developer may evaluate alternative surfactants if the resulting product meets quality, safety, and comparability requirements.

Does the Tysabri prefilled syringe create separate patent risk?

Yes. The syringe, needle system, stopper, silicone level, injection-force profile, and subcutaneous administration method can create separate patent and freedom-to-operate issues.

Can a Tysabri biosimilar receive interchangeable status?

Potentially. Interchangeability requires additional FDA evidence beyond ordinary biosimilarity and depends on the sponsor’s switching and clinical development strategy.

Are Tysabri excipients an attractive standalone investment?

Generally no. The larger commercial opportunities are integrated offerings that combine excipient quality, protein-stability analytics, container-closure systems, device compatibility, and regulatory support.

References

1. U.S. Food and Drug Administration. (2023). Tysabri (natalizumab) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov/drugs/biosimilars
3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
5. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §7002.